Great progress has been made in recent years to reduce the high level of suffering caused
by malaria worldwide. Notably, the use of insecticide-treated mosquito nets for malaria …

Despite substantial scientific progress over the past two decades, malaria remains a
worldwide burden that causes hundreds of thousands of deaths every year. New, affordable …

The last two decades have seen a surge in antimalarial drug development with product
development partnerships taking a leading role. Resistance of Plasmodium falciparum to the …

This review provides a brief assessment of the methodological field of trifluoromethylation
and its possible impact on the development of new CF 3-containing pharmaceuticals …

Malaria elimination has recently been reinstated as a global health priority but current
therapies seem to be insufficient for the task. Elimination efforts require new drug classes …

Primaquine was firstly synthesized in 1946 in the USA, and is the most representative
member of the anti-malarial 8-aminoquinolines. Six decades have passed and primaquine …

Plasmodium vivax is the major species of malaria parasite outside Africa. It is especially
problematic in that the infection can relapse in the absence of mosquitoes by activation of …

Canine leishmaniasis (CanL) is a parasite-borne disease mainly induced by Leishmania
infantum in the Old World and Leishmania chagasi (infantum) in the New World. CanL is a …

Over the past decade, there has been a transformation in the portfolio of medicines to
combat malaria. New fixed-dose artemisinin combination therapy is available, with four …

The eradication of malaria will only be possible if effective, well-tolerated medicines kill
hypnozoites in vivax and ovale malaria, and thus prevent relapses in patients. Despite …